Flu Hospitalization Rate Week 20: Market Near Certain

The CDC’s flu hospitalization surveillance data has effectively called this one. Traders have priced the Week 20 hospitalization rate landing in the 85–90 range at 97.2% probability, leaving almost no room for surprise. This is a near-resolved contract, not an open question.

The market asks whether the weekly flu hospitalization rate for Week 20 of 2026 falls between 85 and 90 per 100,000. YES trades at $0.97. NO trades at $0.03. The contract resolves May 29, 2026. Total volume is $1,400.

How the Week 20 Flu Hospitalization Contract Works

This contract resolves YES if the CDC’s FluSurv-NET weekly hospitalization rate for epidemiological Week 20 (ending May 17, 2026) is confirmed between 85 and 90 per 100,000 population. The CDC publishes this figure through its weekly FluView report. Resolution occurs when the official rate is confirmed and the market closes May 29, 2026.

• YES ($0.97, 97.2% implied probability): CDC Week 20 rate confirmed between 85 and 90 per 100,000.
• NO ($0.03, 2.8% implied probability): CDC Week 20 rate falls outside this range, into any adjacent band including 80–85, 90–95, 95–100, 100+, or below 80.

The NO outcome requires the CDC’s confirmed rate to miss the 85–90 band entirely. That means a late-season hospitalization surge pushing the rate above 90, or an unexpectedly sharp decline pulling it below 85. At this point in the flu calendar, late May represents the tail end of influenza season. Rates falling sharply from peak winter levels is the norm. A rate above 90 this late would be historically unusual. A rate below 85 is the more realistic NO path, but traders are clearly not pricing that as likely.

Sponsored Partner

Momentum and Market Signals

The trend score of 20 reflects a settled, low-volatility contract. No meaningful 1-hour or 24-hour price movement is on record. The market has absorbed the available CDC data and stopped moving.

Total volume is $1,400. The 24-hour volume is $127. Liquidity stands at $3,735. This is a thin market by any standard. Volume below $1,000 in active trading means price could move sharply if new data contradicts the current consensus, but the CDC Week 20 figure is now close enough to the resolution date that a surprise is unlikely to materialize in time. The liquidity pool actually exceeds the trading volume, which signals no serious contest between buyers and sellers.

• YES price holds at $0.97 with no recorded directional movement in the past 24 hours, indicating trader consensus has been stable and no new data has disrupted it.
• NO price at $0.03 reflects a residual uncertainty that exists on paper more than in practice, given where the flu season calendar sits.
• The $127 in 24-hour volume is consistent with a contract that the market has already treated as resolved in all but formality.
• Thin liquidity means any trader moving even a few hundred dollars could technically shift the displayed price, but no one appears motivated to do so.
• Related health markets show mixed signals: Hantavirus pandemic probability sits at 5%, Measles cases in the U.S. at 100%, pointing to an active but differentiated disease-tracking environment on this platform.

Lines Analysis: What the CDC Data Supports

Here’s what the measurements are telling us. The CDC’s FluSurv-NET surveillance network tracks laboratory-confirmed flu hospitalizations across a network of hospitals covering roughly 9% of the U.S. population. By Week 20, the 2025–2026 flu season has passed its winter peak. Historical CDC data consistently shows hospitalization rates declining through April and May. A rate in the 85–90 range for late May is consistent with a season winding down from a moderately active peak. Traders are not pricing uncertainty here. They are pricing science.

The primary risk to the NO side is a data revision. The CDC sometimes revises preliminary weekly figures as more hospital reporting comes in. A preliminary rate landing in the 85–90 band could theoretically shift on revision. That is a narrow path. It requires not just a revision but a revision large enough to move the rate outside a five-point band. The data doesn’t care about the politics of whether traders want drama in this contract. The biology says flu season is winding down, and the numbers reflect that.

• The CDC FluView report for Week 20 is the single data release that resolves this contract. Any revision before May 29 would be the only repricing catalyst.
• A sudden late-season influenza B or novel strain surge could theoretically push rates above 90, but no current surveillance signals support that scenario.
• The 97.2% probability reflects trader confidence that the current reported rate, or something very close to it, will be confirmed by resolution.
• Thin volume means this price is not the product of large-scale institutional conviction. It is the product of a small number of traders agreeing there is nothing left to argue about.

Total volume of $1,400 makes this one of the lowest-liquidity science contracts on the board. The market is pricing uncertainty, not science, in most cases. Here, it is pricing science directly. The CDC’s trajectory through Week 20 points cleanly at the 85–90 band, and no one is seriously betting otherwise.

LINES VERDICT

NEAR CERTAIN YES

The CDC’s Week 20 flu hospitalization trajectory and the late-season calendar both support the 85–90 range. No credible data signal points toward a miss.

What the market says: At 97.2% implied probability, this contract is functionally resolved before its May 29 close. Thin volume means price could technically shift on a data revision, but no revision signal exists.

Key unknown: A CDC FluView revision to the Week 20 preliminary rate before May 29 is the only event that could reprice this contract. That is an extremely narrow path given how close the resolution date is.